Skip to main content

Evaluating Outpatient Teclistamab Administration in Multiple Myeloma With Robert Rifkin, MD, FACP

Oncology Data Advisor® · Evaluating Outpatient Teclistamab Administration in Multiple Myeloma: Robert Rifkin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, MD, FACP, a Board-Certified Medical Oncologist and Hematologist at the Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss his study and presentation on the OPTEC trial, in which administration of the bispecific antibody teclistamab will be eva...

Continue reading

Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD, FACP

At the recent 64th American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, Medical Oncologist and Hematologist at Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss the research that he presented, titled Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry.  

Continue reading